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DNA repair pathways are triggered to maintain genetic stability and integrity when
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents.
The deregulation of DNA repair pathways is associated with the initiation and progression
of cancer. As the primary anti-cancer therapies, ionizing radiation and chemotherapeutic
agents induce cell death by directly or indirectly causing DNA damage, dysregulation of the
DNA damage response may contribute to hypersensitivity or resistance of cancer cells to
genotoxic agents and targeting DNA repair pathway can increase the tumor sensitivity to
cancer therapies. Therefore, targeting DNA repair pathways may be a potential therapeutic
approach for cancer treatment. A better understanding of the biology and the regulatory
mechanisms of DNA repair pathways has the potential to facilitate the development of
inhibitors of nuclear and mitochondria DNA repair pathways for enhancing anticancer
effect of DNA damage-based therapy.
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THE DNA REPAIR PATHWAYS
A variety of endogenous and exogenous DNA-damaging agents such as UV light, ionizing radiation
(IR) and chemotherapeutic agents can lead to DNA lesions, including mismatches, single-strand
breaks (SSBs), double-strand breaks (DSBs), chemical modiﬁcations of the bases or sugars, and
interstrand or intrastrand cross-links. If the damage is not corrected, it will cause genomic instability
and mutation, which is one of the cancer hallmarks (Hanahan and Weinberg, 2011). In order to
prevent this situation, cells have evolved a series of mechanisms called DNA damage response (DDR)
in order to deal with such lesions. DDR is a complex network that functions in different ways to
target various DNA lesions, including signal transduction, transcriptional regulation, cell-cycle
checkpoints, induction of apoptosis, damage tolerance processes, and multiple DNA repair pathways
(Figure 1) (Giglia-Mari et al., 2011; Tian et al., 2015).
In mammalian cells, the two main organelles containing DNA are nucleus and mitochondria.
Nuclear DNA (nDNA) repair systems are divided into the following major pathways: 1) direct
reversal, which mainly repairs the lesion induced by alkylating agents, 2) base excision repair (BER),
aiming at DNA breaks (SSBs) and non-bulky impaired DNA bases, 3) nucleotide excision repair
(NER), correcting bulky, helix-distorting DNA lesions, 4) mismatch repair (MMR), repair of
insertion/deletion loops (IDLs) and base-base mismatch, 5) recombinational repair, which is
further divided into homologous recombination repair (HRR) and non-homologous end joining
(NHEJ), primarily functioning at DNA double strand breaks, 6) alternative nonhomologous end
joining (alt-NHEJ, MMEJ), involved in repair of DSBs, 7) translesion synthesis (TLS), which is more
likely to be a DNA damage tolerance mechanism (Jackson and Bartek, 2009; Hosoya and Miyagawa,
2014). Mitochondrial DNA (mtDNA) repair pathways, including the direct reversal, BER, MMR,
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FIGURE 1 | DNA damage response. DNA damage is caused by endogenous agent oxygen species (ROS) or exogenous agents such as UV light, ionizing radiation
(IR) and chemotherapy agents. DNA damage response (DDR) is induced to deal with the lesions, including signal transduction, transcriptional regulation, cell-cycle
checkpoints, induction of apoptosis, multiple DNA repair pathways as well as damage tolerance processes. DNA repair pathways include nuclear and mitochondrial
DNA repair pathways. Direct repair, BER, MMR and recombinational repair (HR and NHEJ) are existence in both nuclear and mitochondrial repair systems. NER has
been reported only appearance in nucleus, and the existence of TLS pathway in mitochondria is unknown. NDNA, nuclear DNA; MtDNA, mitochondrial DNA; BER, base
excision repair; HR, homologous recombination repair; NHEJ, non-homologous end joining; MMR, mismatch repair; TLS, translesion synthesis; NER, nucleotide
excision repair.

TLS and double-strand break repair (DSBR), can repair damaged
DNA to maintain mitochondria genetic integrity, protect
mtDNA against oxidative damage, and promote cell survival
(Ohta, 2006; Saki and Prakash, 2017).

(Squatrito et al., 2010). The human syndrome hereditary
nonpolyposis colorectal cancer (HNPCC), which connects with
high degrees of microsatellite instability, is caused by germline
mutations in MMR genes, and the tumorigenesis of this disease is
connected with the defect in the MMR pathway (Hampel et al.,
2005). People who carry an MMR gene mutation have the
increased risk of a wide variety of cancers than their
noncarrier relatives (Win et al., 2012). Two important
homologous recombination (HR) DNA repair-related genes,
BRCA1 and BRCA2 germline mutant confer the genetic
predisposition to breast, ovarian cancer and pancreatic cancer
(Riaz et al., 2017). In addition, the tumor microenvironment
characteristic of hypoxia, low pH and nutrient deﬁciency, can
give rise to genomic instability and tumor progress through
downregulating DNA repair pathway. It has been reported
that hypoxic circumstance can result in the reduction of
MLH1 expression, a core protein in the MMR pathway
(Mihaylova et al., 2003). The downregulation of RAD51, a key
mediator of HRR, was observed in multiple cancer cell types

ROLE OF DNA REPAIR PATHWAYS IN
CANCER BIOLOGY
DNA repair pathways play an important role in the maintenance
of genome stability and integrity through correcting the impaired
DNA that may contribute to carcinogenesis (Clementi et al.,
2020). Numerous studies have indicated that certain cancers are
associated with the defect or mutation in the proteins of nuclear
or mitochondrial DNA repair pathways (Pearl et al., 2015;
Cerrato et al., 2016). For example, the defect in the
ATM–Chk2–p53 pathway, which plays a crucial role in DNA
double-strand breaks repair, promoted glioblastoma multiforme
(GBM) formation and contributed to GBMs radiation resistance
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the therapeutic efﬁcacy of chemotherapeutic alkylating agents
(Maki, Murakami, 2005). Lomeguatrib (called O6-(4bromothenyl) guanine, as well as PaTrin-2), another
pseudo-substrate tested in clinical trials, has been shown to
increase the therapeutic index of methylating agent
temozolomide in nude mice bearing A375M human
melanoma xenografts and patients with advanced solid
tumors (Middleton et al., 2002; Ranson et al., 2006).
Bobustuc GC et al. demonstrated that inhibition of MGMT
suppressed the expression of survivin and enhanced the
cytotoxicity of gemcitabine in pancreatic cancer (Bobustuc
et al., 2015). Another approach to MGMT inactivation is to
silence the MGMT gene expression through its promoter
methylation. Several studies in animal models have
suggested that the therapy of MGMT gene silence was able
to overcome TMZ resistance and increase tumor cell death
(Viel et al., 2013). Clinical study indicated that patients with
glioblastoma containing a methylated MGMT promoter
obtained more beneﬁts from TMZ than those who did not
have a methylated MGMT promoter (Hegi et al., 2005). Lately,
it has been conﬁrmed that MGMT gene methylation can be a
biomarker for temozolomide (TMZ) treatment and a potent
prognostic factor in patients with GBM (Kim et al., 2012;
Iaccarino et al., 2015; Zhao et al., 2016; Binabaj et al., 2018).
However, according to the data from National Cancer database
(NCDB) indicated that only 4.9% of GBM patients have
MGMT promoter methylation. Even though MGMT
promoter methylation status has prognostic value, it is
ignored in the United States (Lee et al., 2018). More
researches need to conduct to identify the prognostic value
of MGMT promoter methylation in tumor patients responding
to alkylating agents.

induced by hypoxia, suggesting that the hypoxic tumor
microenvironment can suppress the HRR pathway to cause
genetic instability (Bindra et al., 2004; Lu et al., 2011). Tumor
hypoxia also regulated the DDR by driving alternative splicing
(Memon et al., 2016). Study in human pulmonary epithelial cells
has found that the acidic conditions delayed DNA damaging
compounds benzo[a]pyrene (B[a]P) metabolism and inhibited
NER capacity, ultimately enhanced B[a]P-induced DNA damage
(Shi et al., 2017). Recent studies have shown that extracellular
nutrients have signiﬁcant effects on genome integrity. Glutamine
is the main source of carbon and nitrogen for tumor cells. Lack of
glutamine led to DNA alkylation damage by inhibiting ALKBH
activity and increased the sensitivity of cancer cells to alkylating
agents (Tran et al., 2017). Glucose starvation also enhanced
radiosensitivity of tumor cells by reducing DNA double-strand
break (DSB) repair (Ampferl et al., 2018). Thus, the dysregulation
of DNA repair pathways can contribute to the development of
cancer by promoting genomic instability and mutation in
mammal cells.

TARGETING DNA REPAIR PATHWAYS IN
CANCER THERAPY
The most common cancer treatments, including chemo- or
radiotherapy, are designed to induce cell death by direct or
indirect DNA damage. However, tumor cells can initiate DNA
repair pathways to resist these anticancer agents during chemoor radiotherapy. Therefore, combination of the nuclear or
mitochondrial DNA repair pathway inhibitors with anticancer
agents may increase the tumor cell sensitivity to these agents.

O-6-Methylguanine-DNA Methyltransferase
(MGMT)

Base Excision Repair
A number of investigations have shown that inhibition of BER
pathway can enhance the sensitivity of cancer cells to alkylating
agents and radiotherapy (Neijenhuis et al., 2005; Gao et al., 2019).
The primary methods to prevent the activity of BER pathway
focus on the development of AP endonuclease 1 (APE1) or Poly
(ADP-ribose) polymerase (PARP) inhibitors.
Several studies indicated that methoxyamine (MX), a small
alkoxyamine that can bind with the free aldehyde of AP site to
prevent APE1 cleavage at AP sites, thereby inhibiting APE-1
endonuclease
activity.
Combined
treatment
with
chemotherapeutic alkylating agent such as TMZ and BCNU
could reinforce the cytotoxicity of alkylating agent by targeting
BER pathway (Liu et al., 2003; Montaldi and Sakamoto-Hojo,
2013). Recently, based on preclinical studies, several clinical trials
were conducted, for example combination therapy with MX and
TMZ in patients with advanced solid tumors has completed
(NCT00892385). Currently, phase Ⅰ clinical trials of MX in
combination of TMZ is undergoing in patients with relapsed
solid tumors and lymphomas (NCT01851369). MX combination
with pemetrexed disodium, cisplatin, is now investigating in
phase Ⅰ/II stage in patients with advanced malignant solid
neoplasm (NCT02535312). Lucanthone, a topoisomerase II
inhibitor as well as an APE1 endonuclease inhibitor, has been

The role of MGMT is to remove alkyl adducts from the O6
position of guanine. Thus, the protective effect of MGMT could
diminish the cytotoxic effects of alkylating agents (Middleton and
Margison, 2003), suggesting that MGMT activity is likely to be a
useful marker of the sensitivity of cancer cells to alkylating agents.
It has been reported that high MGMT expression in tumor cell is
associated with the resistance to 1,3- bis- (2-chloroethyl) -1nitrosourea (BCNU) and temozolomide (TMZ) (Happold et al.,
2018; Hsu et al., 2018), which target the O6-position of guanine,
resulting in cytotoxic and mutagenic DNA adducts (Rabik et al.,
2006). Recently, researchers found that MGMT-mediated the
resistance to DNA alkylating agents in cancer cell is profoundly
dependent on the DNA repair enzyme PARP. Combination of
temozolomide with PARP inhibitors (PARPi) in MGMT-positive
cancer cells enhanced the anticancer effects (Erice et al., 2015; Jue
et al., 2017).
The inactivation of MGMT in tumor cells has been
appreciated as a therapeutic target for sensitizing cells to
O6-alkylating agents (Maki et al., 2005). In vitro and in vivo
studies demonstrated that O6-Benzylguanine (O6-BG), a
typical pseudo-substrate that was developed to inactivate
MGMT, in combination with O6-alkylating agents increased
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FIGURE 2 | Mechanism and function of PARP and PARP inhibitors. The catalytic function of PARP1 is activated through binding to the SSBs site cuased by
alkylating agents. Activated PARP1 undergo PARylation and recruitment of a serials of key DNA repair effectors involved in BER to repair DNA lesion. Finally, PARP1
release from DNA and regain inactive state. PARP inhibitors binds the catalytic site of PARP and impaired of the enzymatic activity of PARP which “trap” PARP1 on DNA,
results in suppression of the catalytic cycle of PARP1 and BER. Trapping PARP1 on DNA lesion also collapses DNA replication fork, therefore transforming SSBs
into genotoxic DSBs. This type of DNA lesion would normally induce HR for repairing damaged DNA. However, if HR-defective exist in tumor cells, including BRCA1/2
deﬁciency or mutation, another less effective and error-prone DSBs repair pathway NHEJ or alt-NHEJ could be utilized, which causing genomic instability, chromosomal
fusions/translocations and subsequently inducing cell death. SSBs, single-strand breaks; DSB, double-strand break; BER, base excision repair; alt-NHEJ, alternative
nonhomologous end joining; NHEJ, non-homologous end joining; HR, homologous recombination repair.

shown to reinforce the cell killing effect of alkylating agents in
human breast cancer cell line MDA-MB-231 (Luo and Kelley,
2004). Lucanthone combination with radiation and TMZ in GBM
patients was tested in phase Ⅱ clinical trial (NCT01587144).
However, it was terminated in 2016. Another phase II clinical
trial investigating lucanthone combination with radiation in
patients with brain metastases from non-small cell lung cancer
was withdrawn due to drug issues (NCT02014545).
PARP family is composed of 17 members, of which PARP1 and
PARP2 are well-recognized DNA damage sensors, especially PARP1.
PARP1 detect the region of damaged DNA and play a key role in
several DNA repair pathway including BER, HHR and MMEJ
(Konecny and Kristeleit, 2016). While PARP1 is best studied in
BER and the mechanism of PARP inhibitor (PARPi) is based on
trapping PARP1 on SSBs DNA site to inhibit BER repair. Finally, it
converted SSBs into DSBs and impelled cell death in HR-deﬁciency
tumor, for example BRCA1/2 mutations, RAD51 deﬁciency
(Figure 2) (Konecny and Kristeleit, 2016; Brown et al., 2017; Lord
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and Ashworth, 2017; Oplustil O’Connor et al., 2016). In 2005, two
pre-clinical researches published in nature indicated that BRCA1 or
BRCA2 deﬁcient cells highly sensitized to PARP inhibition (Farmer
et al., 2005; Bryant et al., 2005). Based on the concept of “synthetic
lethality”-targeting either gene alone in a synthetic lethal pair is
tolerated, but simultaneous targeting both genes is lethal, researchers
applied PARPi to BRCA mutation tumors (Dhillon et al., 2016).
Several clinical trials using PARPi including Olaparib, Veliparib,
Rucaparib (Table 1) as monotherapy for the treatment of patients
with germline BRCA1/2 mutation tumors including advanced breast
cancer, ovarian cancer, pancreatic cancer and prostate cancer
presented signiﬁcantly antitumor effect (Kaufman et al., 2015;
Robson et al., 2017; Moore et al., 2018; Golan et al., 2019).
Olaparib as maintenance therapy also signiﬁcantly prolonged
progression-free survival in advanced ovarian cancer patients with
HRD-positive tumors who have achieved ﬁrst-line standard therapy
including bevacizumab. It has been approved by FDA for
utilization of Olaparib in patients with advanced germline
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TABLE 1 | DNA repair pathway inhibitors in current clinical trials.
Targeting
protein

DNA repair
pathway

Inhibitors

Clinical
status

Disease state

Intervention/treatment

NCT number

Status

PARP1/
PARP2

BER

Olaparib (AZD-2281)

Phase II

Olaparib

NCT03786796

Recruiting

Olaparib

NCT04515836

Olaparib
Olaparib

NCT03367689
NCT03448718

Not yet
recruiting
Recruiting
Recruiting

Olaparib

NCT03205761

Recruiting

Phase II

Metastatic renal cell carcinoma with DNA
repair gene mutations
Mesothelioma with homologous
recombination deﬁciency
Non-BRCA metastatic breast cancer (MBC)
Metastatic urothelial cancer with somatic DNA
damage response (DDR) alterations
Metastatic breast cancer with BRCA1 and/or 2
promoter methylation
Cisplatin-resistant germ cell tumor

Olaparib

NCT02533765

Phase I
Phase I

Advanced cancer
Triple negative breast cancer (TNBC)

Olaparib, AZD5363
Olaparib, radiation therapy

NCT02338622
NCT03109080

Phase Ⅲ

HER2-ve metastatic breast cancer patient

Olaparib

NCT03286842

Phase Ⅳ

BRCA or HRR + mutated ovarian cancer

Olaparib

NCT02476968

Phase
Phase
Phase
Phase
Phase
Phase
Phase

Niraparib
Niraparib
Niraparib, osimertinib
Niraparib
SYD985, niraparib
Nirapairb
Talazoparib

NCT03497429
NCT04080284
NCT03891615
NCT03601923
NCT04235101
NCT03709316
NCT01286987

Phase I
Phase II

Advanced solid tumors
Uterine serous carcinoma
EGFR-mutated advanced lung cancer
Pancreatic cancer
Solid tumors
Ovarian cancer
BRCA mutation-associated breast and ovarian
cancers, pancreatic and small cell lung cancer
Leukemia with cohesin complex mutation
Advanced cancer with DNA repair variations

Active, not
recruiting
Completed
Active, not
recruiting
Active, not
recruiting
Active, not
recruiting
Completed
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Completed

Talazoparib
Talazoparib

NCT03974217
NCT04550494

Phase II
Phase I

Triple negative breast cancer
Pancreatic cancer

NCT03901469
NCT01908478

Phase I

Refractory Solid Tumors

Talazoparib, ZEN003694
Veliparib, gemcitabine,
radiation
Veliparib, VX-970, cisplatin

Phase II

Phase II

Malignant glioma without H3 K27M or
BRAFV600 mutations
Metastatic breast cancer with BRCA1/2 gene
mutation
Refractory testicular germ cell cancer

Phase I
Phase I

Advanced malignant solid neoplasm
Advanced solid tumor

Phase II

Nonmetastatic, hormone-sensitive prostate
cancer
Metastatic castration resistant prostate cancer

Phase II
Phase II
Phase II
Phase II

Niraparib

Talazoparib

Veliparib (ABT-888)

I
II
I
II
I
Ⅲ
I

Phase II

Rucaparib

Phase I
Phase II

APE1/Ref-1
DNA-PK

DNA-PK/
mTOR

BER

BER
NHEJ

NHEJ

NCT03581292
NCT01009788

Gemcitabine, carboplatin,
veliparib
Dinaciclib, veliparib
Rucaparib, camsylate

NCT01434316
NCT03521037

Rucaparib

NCT03533946

Rucaparib, enzalutamide,
abiraterone
Rucaparib, nivolumab

NCT04179396

Recruiting

NCT03824704

Rucaparib

NCT04171700

Active, not
recruiting
Recruiting

2X-121

NCT03562832

NCT02860819

2X-121

Phase II

Methoxyamine
(TRC102)

Phase I/II

Relapsed solid tumors and lymphomas

TRC102

NCT01851369

Phase I/II

Solid tumors or mesothelioma

NCT02535312

Phase I

Stage IIIA-IV non-small cell lung cancer

Cisplatin, methoxyamine,
pemetrexed disodium
Radiation, cisplatin

Phase I
Phase I

Advanced solid tumors
Locally advanced rectal cancer

Phase I

Advanced solid tumor

Phase I/II

Locally advanced rectal cancer

VX-984 (M9831)

Phase I

Advanced solid tumor

CC-115

Phase I

Advanced solid tumors, hematologic
malignancies

APX3330 (E3330)
MSC2490484A
(M3814)
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Active, not
recruiting
Recruiting
Active, not
recruiting
Active, not
recruiting
Recruiting
Active, not
recruiting
Recruiting

High-grade serous or endometroid ovarian
cancer
Solid tumors and with deleterious mutations in
HRR genes
Metastatic breast cancer

Phase II

APE1

Radiation, temozolomide,
veliparib
ABT-888, temozolomide

NCT02723864

Recruiting
Not yet
recruiting
Recruiting
Completed

APX3330
M3814, avelumab,
radiation
Radiation, cisplatin,
MSC2490484A
M3814, capecitabine,
radiation
IV pegylated liposomal
doxorubicin, VX-984
CC-115

NCT02535325

Active, not
recruiting
Recruiting

NCT03375086
NCT03724890

Active, not
recruiting
Completed
Recruiting

NCT02516813

Recruiting

NCT03770689

Recruiting

NCT02644278

Completed

NCT01353625

Active, not
recruiting
(Continued on following page)
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TABLE 1 | (Continued) DNA repair pathway inhibitors in current clinical trials.
Targeting
protein

DNA repair
pathway

Inhibitors

Clinical
status

Disease state

Intervention/treatment

NCT number

Status

ATM

HR

AZD0156

Phase I

Advanced solid tumors

NCT02588105

Active, not
recruiting

AZD1390

Phase I
Phase I

Brain cancer
Non small cell lung cancer

NCT03423628
NCT04550104

AZD6738
(Ceralasertib)

Phase II
Phase I
Phase II

Biliary tract cancer
Leukemia, myelodysplastic syndrome
Relapsed small cell lung cancer subjects

AZD0156, olaparib,
irinotecan, ﬂuorouracil,
folinic acid
Radiation, AZD1390
Radiation, olaparib,
AZD1390
AZD6738, durvalumab
AZD6738
Durvalumab, AZD6738

NCT04298008
NCT03770429
NCT04361825

Phase II

Clear cell renal cell carcinoma, locally
advanced pancreatic cancer, locally advanced
malignant solid neoplasm
Refractory cancer
Recurrent ovarian cancer
IDH1 and IDH2 mutant tumors
Solid tumor, leiomyosarcoma, osteosarcoma
Small cell cancers and extrapulmonary small
cell cancers
Refractory solid tumors

AZD6738, olaparib

NCT03682289

Recruiting
Not yet
recruiting
Recruiting
Recruiting
Enrolling by
invitation
Recruiting

AZD6738, paclitaxel
Olaparib pill, AZD6738
Ceralasertib, olaparib
M6620
Topotecan, VX-970

NCT02630199
NCT03462342
NCT03878095
NCT03718091
NCT02487095

Recruiting
Recruiting
Recruiting
Recruiting
Recruiting

Veliparib, VX-970, cisplatin

NCT02723864

Berzosertib, topotecan
hydrochloride
Berzosertib, cisplatin,
gemcitabine hydrochloride
LY3023414, prexasertib
Prexasertib

NCT03896503

Active, not
recruiting
Recruiting

NCT04032080
NCT02808650

Prexasertib, irinotecan

NCT04095221

Prexasertib

NCT03414047

Prexasertib, olaparib

NCT03057145

MK-8776, cytarabine
SRA737, gemcitabine,
cisplatin
Adavosertib

NCT00907517
NCT02797977

ATR

HR

VE-822 (VX-970,
M6620, berzosertib)

Phase I
Phase II
Phase II
Phase II
Phase1/II
Phase I
Phase II

CHK1

HR

Phase II

Small cell lung cancers and small cell cancers
outside of the lungs
Metastatic urothelial cancer

Phase II
Phase II

Triple negative breast cancer
Recurrent or refractory solid tumors

Phase I/II

Phase I

Desmoplastic small round cell tumor,
rhabdomyosarcoma
Platinum-resistant or refractory recurrent
ovarian cancer
Advanced solid tumors

MK-8776
SRA737

Phase I
Phase I/II

Acute leukemias
Advanced solid tumors

Adavosertib
(AZD1775)

Phase II

Uterine serous carcinoma

Phase I
Phase I/II

Advanced solid tumors
Relapsed or refractory solid tumors

Phase I

Newly diagnosed or recurrent glioblastoma

Prexasertib

Phase II

WEE1

HR

Adavosertib
Adavosertib, irinotecan
hydrochloride
Adavosertib, radiation
therapy, temozolomide

NCT02567409

NCT04590248
NCT04462952
NCT02095132
NCT01849146

Active, not
recruiting
Recruiting
Active, not
recruiting
Recruiting
Active, not
recruiting
Active, not
recruiting
Terminated
Completed
Not yet
recruiting
Recruiting
Active, not
recruiting
Active, not
recruiting

Abbreviations: PARP, Poly (ADP-ribose) polymerase; APE1, AP endonuclease 1; Ref-1, redox factor-1; DNA-PK, DNA-dependent protein kinase; mTOR, mammalian target of rapamycin;
ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; CHK1, checkpoint kinase 1; WEE1, Wee1-like protein kinase.

DNA-dependent protein kinase (DNA-PK), a member of
the PI3K-related protein kinase (PIKK) family, is involved
in DSBs repair pathway via non-homologous end joining
(NHEJ) (Jette and Lees-Miller, 2015). It has been reported
that DNA-PK activity plays a role in chemo-radiotherapy
resistance (Wang Y. et al., 2018; Stefanski et al., 2019;
Alikarami et al., 2017; Liu et al., 2015). Selective DNA-PK
inhibitor have been developed, including NU7026 (Dolman
et al., 2015), NU7441 (Yang et al., 2016), IC87361 and
SU11752 (Shinohara et al., 2005). They could inhibit DSBs
repair pathway and enhance the sensitivity of cancer cells to
ionizing radiation or/and chemo-potentiation such as
doxorubicin (Ciszewski et al., 2014). The combination of
DNA-PK inhibitor M3814 with type II topoisomerase
inhibitors, including doxorubicin, etoposide and pegylated
liposomal doxorubicin, enhanced the efﬁcacy of type II

BRCA-mutated ovarian cancer following three or more prior
lines of chemotherapy (Kim et al., 2015). On May 19, 2020, the
FDA also approved Olaparib for patients with metastatic
castration-resistant prostate cancer (mCRPC) carrying HRR
gene-mutated based on NCT02987543. PAPR1 inhibitors in
combination with IR or with other different anticancer agents
are currently undergoing clinical trials for treatment of
patients with BRCA1/2 mutation or HRR-deﬁciency
advanced solid tumors, which shown promising clinical
activity (Bang et al., 2017; Wilson et al., 2017; Loibl et al.,
2018; Coleman et al., 2019; Farago et al., 2019;
Konstantinopoulos et al., 2019; Liu et al., 2019).

Double Strand Breaks Repair
Among various DNA lesions, DSBs is the leading lethal
damage that leads to cell death and genetic mutations.
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topoisomerase inhibitors in ovarian cancer xenografts (Wise
et al., 2019). Several novel DNA-PK inhibitors including
MSC2490484A, VX-984 (M9831), M3814 are under clinical
trial as single-agent or combination with Chemo-radiotherapy
(Table 2). Alexander K. Tsai et al. recently found that NU7441
combination with a multikinase inhibitor regorafenib altered
immune microenvironment of melanomas and enhanced the
efﬁcacy of various immunotherapies (Tsai et al., 2017).
Ataxia-teleangectasia mutated (ATM) and ATM-RAD3related (ATR) protein, like DNA-PK protein, are the members
of PIKK family. They work as a transducer of the DSB signal, and
are involved in the repair of DNA DSBs (Weber and Ryan, 2015).
A large of ATM inhibitors, including KU-55933, KU-60019, KU59403, CP-466722, AZ31, AZ32, AZD0156, and AZD1390, have
been developed and their antitumor effects have been investigated
(Jin and Oh, 2019). It has been reported that human tumor cells
treated with KU-55933, a speciﬁc inhibitor of the ATM kinase,
could sensitize tumor cells to the cytotoxic effects of IR and DNA
DSBs-inducing chemotherapeutic agents such as etoposide,
doxorubicin, and camptothecin (Hickson et al., 2004; Hoey
et al., 2018). KU-60019, an improved ATM kinase inhibitor,
acts as a highly effective radio-sensitizer in human glioma cells
(Biddlestone-Thorpe et al., 2013). AZD0156, a newly discovered
ATM inhibitor, has the potential to promote the survival of
leukemia-bearing mice and now is under clinical trial
(Morgado-Palacin et al., 2016). Preclinical study demonstrated
that ATM inhibitor AZD1390 enhanced the radiosensitivity of
tumor cells and extended animal survival in preclinical brain
tumor models (Durant et al., 2018). AZD1390, as a
radiosensitizer, is now undergoing two clinical trials in
patients with brain cancer (NCT03423628) or non small cell
lung cancer (NCT04550104). Many inhibitors aiming at both
ATM and DNA-PK have been reported to have great potential as
a chemo- and radiotherapy sensitizing agents in cancer therapy
(Powell and Bindra, 2009).
The cell cycle checkpoint kinases CHK1 and CHK2 are
downstream substrates of ATM /ATR, which act as the
“central transducers” of the DDR (Pilie et al., 2019).
Activation of these pathways is essential for the proper
regulation of checkpoint and DNA repair (Smith et al., 2010).
The ATM–Chk2 and ATR–Chk1 pathways respond to different
DNA damages, ATM is activated at DSBs, whereas ATR is
recruited to tracts of ssDNA (Di Benedetto et al., 2017).
Subsequently, CHK1 and CHK2 activated by ATR and ATM
respectively upon their recruitment to DNA damage sites. Protein
kinase WEE1 functioned as furthest downstream in ATR/CHK1
pathway, which is indirectly regulated by DNA damage (Cleary
et al., 2020). WEE1 actives the G2/M cell cycle checkpoint by
impeding cyclin-dependent kinase 1 and 2 (CDK1/2) activity,
thereby inducing cell cycle arrest and promoting DNA damage
repair. Inhibition of WEE1 causes aberrant DNA replication and
replication-dependent DNA damage in cells by suppressing
CDK2 (Guertin et al., 2013). Recently, compounds targeting
CHK1 are currently in clinical trials (Table 1). The ﬁrst-inclass WEE1 kinase inhibitor AZD1775 is also undergoing a
series of clinical trials as monotherapy or in combination with
other therapies (Table 1).
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Recently, the exploration of novel anticancer strategies aiming at
the differences in mitochondrial function and structure between
normal cells and cancer cells has received intensive attention
(Porporato et al., 2018). However, there are few studies that have
discovered new anticancer approaches via targeting mtDNA
repair pathway.
Like nDNA, efﬁcient mtDNA repair pathway, especially BER
pathway that mainly repairs ROS-induced lesion, may play an
important role in cellular resistance to cancer therapeutic agents.
MtDNA D-loop mutations were common in gastrointestinal cancer
and correlated with carcinoma progression (Wang B. et al., 2018). It
has been found that human breast cancer cells defective of mtDNA
repair are more sensitive to oxidative damage than the control cells
(Shokolenko et al., 2003). Grishko V I et al indicated that mtDNA
repair pathways played an important role in protecting cells against
ROS in normal HA1 Chinese hamster ﬁbroblasts (Grishko et al.,
2005). Another study clariﬁed that mtDNA repair capacity was
important for cellular resistance to oxidative damage by increasing
their viability following exposure to oxidative stress (Shokolenko
et al., 2003). Ueta E et al demonstrated that downregulation of the
mtDNA repair-associated molecules, mitochondrial transcription
factor A (mtTFA) and Polγ by using inhibitors of PI3K/Akt
signaling in oral squamous cell carcinoma cells (OSC) increased
the susceptibility of radio-sensitive OSC cells and radio-resistant
OSC cells to gamma-rays (Ueta et al., 2008). This observation
implied that PI3K/Akt signal inhibitors can suppress mtDNA
repair capacity. Thus, these inhibitors combined with ionizing
irradiation or chemotherapeutic drugs may be utilized as an
effective strategy in cancer therapy.
DNA glycosylases are involved in the initiation step of BER that
recognizes and removes the abnormal base (Anderson and
Friedberg, 1980). 8-OxoG-recognizing DNA glycosylase 1
(OGG1) is an important DNA glycosylase for repair of 8oxoguanine (8-oxoG), which is one of the major DNA lesions
both of the nDNA and mtDNA, especially in mtDNA (Rachek
et al., 2002). It has been found that tumor cells harboring
overexpressed recombinant OGG1 were more proﬁcient at
repairing of oxidative damage to mtDNA, and had increased
cellular survival under oxidative stress (Rachek et al., 2002;
Yuzefovych et al., 2016). We previously found that Sirt3, a major
mitochondrial NAD+-dependent deacetylase, physically associated
with OGG1 and deacetylated this DNA glycosylase, and that
deacetylation by Sirt3 prevented the degradation of the OGG1
protein and controlled its incision activity (Cheng et al., 2013).
We further showed that regulation of the acetylation and turnover of
OGG1 by Sirt3 played a critical role in repairing mitochondrial DNA
(mtDNA) damage, protecting mitochondrial integrity, and
preventing apoptotic cell death under oxidative stress. We
observed that following ionizing radiation, human tumor cells
with silencing of Sirt3 expression exhibited oxidative damage of
mtDNA, as measured by the accumulation of 8-oxoG and 4,977
common deletion, showed more severe mitochondrial dysfunction,
and underwent greater apoptosis, in comparison to the cells without
silencing of Sirt3 expression. Our results not only reveal a new
function and mechanism for Sirt3 in defending the mitochondrial
genome against oxidative damage and in protecting from the
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TABLE 2 | Inhibitors of DNA repair pathway recently under preclinical studies.
Inhibitor

DNA repair
pathway

Target

Application

References

Lomeguatrib
(PaTrin-2)
Lucanthone
CRT0044876
Methoxyamine

Direct repair

MGMT

BER
BER
BER

APE1
APE1
APE1

Wu et al. (2019), Shi et al.
(2020)
Chowdhury et al. (2015)
Seo and Kinsella (2009)
Oleinick et al. (2016)

APX3330 (E3330)
RI-1

BER
HR

APE1/Ref-1
RAD51

B02

HR

RAD51

AG-14361
A-966492

BER
BER

PARP1
PARP1/2

KU-55933
ETP-46464

HR
HR

VE-821
AZ20
CGK733
NU7026

HR
HR
HR
NHEJ

ATM
ATM/ATR,
mTOR
ATR
ATR
ATM/ATR
DNA-PK

NU7441

NHEJ

DNA-PK

Pancreatic cancer cells; combination with HDACis in ovarian
cancer
Glioblastoma multiforme (GBM) cell
Colon cancer cell lines
Combination with pemetrexed in non-small-cell lung cancer cells
and xenografts
Bladder cancer
Combination with olaparib in breast cancer cells with wild-type
PTEN; combination with radiation in glioma stem cells
Combination with radiation in glioma stem cells; combination with
clinically approved anticancer agents in breast cancer cell
Combination with lestaurtinib in breast cancer cells
Combination with topotecan and radiotherapy on glioblastoma
spheroids
Combination with radiotherapy on glioblastoma spheroids
Single or combination with cisplatin in platinum-sensitive and
-resistant ovarian, endometrial and cervical cancer cell lines
Combination with BETi in myc-induced lymphoma cells
Colorectal adenocarcinoma tumor cells
Human breast cancer cells
Combination with carbon ion irradiation in non-small cell lung
cancer cell
Combination with radiotherapy in non-small cell lung cancer cell

(Fishel et al., 2019)
King et al. (2017), Zhao et al.
(2017)
Huang and Mazin (2014), King
et al. (2017)
Vazquez-Ortiz et al. (2014)
Koosha et al. (2017)
Carruthers et al. (2015)
Teng et al. (2015)
Muralidharan et al. (2016)
Foote et al. (2013)
Alao and Sunnerhagen (2009)
Ma et al. (2015)
Sunada et al. (2016)

Abbreviations: MGMT, O-6-methylguanine-DNA methyltransferase; APE1, AP endonuclease 1; Ref-1, redox factor-1; RAD51, DNA repair protein RAD51 homolog 1; PARP, Poly (ADPribose) polymerase; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; mTOR, mammalian target of rapamycin; DNA-PK, DNAdependent protein kinase;
BETi, BET inhibitors.

genotoxic stress-induced apoptotic cell death, but also provide
evidence supporting a new mtDNA repair pathway. Recently,
researchers also proved that overexpression of mitochondrial
OGG1 decreased breast cancer progression and metastasis
(Yuzefovych et al., 2016).
In conclusion, combination of DNA repair pathway inhibitors
with anticancer agents may enhance the tumor sensitivity to
certain chemotherapeutic drugs and radiation. More effective and
less toxic DNA-damaging agents have been developed and
carried out in preclinical studies (Table 2). Based on the
preclinical data, a number of clinical trials have been launched
to test whether targeting DNA repair pathways can reinforce the
efﬁcacy of some anticancer drugs and beneﬁt cancer patients
(Table 1).

damage repair related genes and DRC, inhibition of NER
pathway signiﬁcantly enhanced the sensitivity of tumor cells to
cisplatin (Oliver, Mercer, 2010; Wang et al., 2011). Low expression of
53BP1, a DDR protein involved in NHEJ, was associated with higher
local recurrence in triple negative breast cancers (TNBC) patients
treated with breast-conserving surgery and radiotherapy, indicating
that 53BP1 may be a predictor of radio-resistance (Neboori et al.,
2012). PTEN Y240 phosphorylation induced by ionizing radiation
(IR), a standard treatment for glioblastoma (GBM) patients,
promoted therapeutic resistance by enhancing DNA repair (Ma
et al., 2019). Inhibiting DNA repair kinases could also prevent
doxorubicin (DOX) resistance in breast cancer cells (Stefanski
et al., 2019). Abnormal DNA repair activity was found in CDK4/
6 inhibitors palbociclib-resistant breast cancer cells, whereas PARP
inhibitors, olaparib and niraparib treatment could signiﬁcantly
inhibit palbociclib-resistant cancer cell viability (Kettner et al.,
2019). In the recent years, immunotherapy is a major
breakthrough in the ﬁeld of cancer treatment. Therefore, the role
of DDR in tumor immunotherapy has attracted much attention.
Studies have shown deﬁciency of a speciﬁc DNA repair pathway was
associated with immune checkpoint blockade (ICB) response. For
example, MMR has been reported as a critical biomarker of response
to immune checkpoint inhibitors in cancer (Le et al., 2017).
Alterations in genes encoding MMR proteins often contribute to
frameshift mutations, resulting in neoantigen generation (Germano
et al., 2017). Phase II clinical trials proved that mismatch
repair–deﬁcient tumors exhibited higher responsive to PD-1
blockade compared with mismatch repair–proﬁcient
tumors(Asaoka et al., 2015). Based on lines of pre-clinical

THE RELATIONSHIP BETWEEN DNA
REPAIR PATHWAYS AND CANCER
THERAPEUTIC RESISTANCE
Resistance to cancer therapy remains the leading cause of treatment
failure in cancer patients. DNA repair capacity (DRC) of tumor cells
has been known to involve in drug resistance, including
chemoradiotherapy, targeted therapy and immunotherapy. DNA
damage inducing drug cisplatin is one of the most widely employed
chemotherapeutic drugs. In a murine model of human lung cancer,
tumor cells were initially effective with cisplatin treatment, but
resistant emerged after prolonged treatment (Oliver et al., 2010).
Cisplatin-resistant tumor cells exhibited higher level of DNA
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and clinical evidence, the US Food and drug Administration
(FDA) has approved anti-PD-1 antibodies for the treatment of
patients with MMR-deﬁcient (Ruiz-Bañobre and Goel, 2019).
On the contrary, researchers also found that colorectal cancer
(CRC) patient with DNA mismatch repair deﬁciency
(dMMR)/a high-level of microsatellite instability (MSI-H)
exhibited intrinsic resistance to immune checkpoint immune
checkpoint inhibitor (Gurjao et al., 2019). Metastatic urothelial
carcinoma (mUC) shown relatively low response rates to PD-1/
PD-L1 blockade (15–24%), whereas the presence of DDR gene
mutations is a potential marker of clinical beneﬁt from anti-PD1/PD-L1 immune checkpoint inhibitors in mUC (Teo et al., 2018).
Preclinical studies have also revealed that suppression of PARP
induced PD-L1 expression and consequently caused
immunosuppression (Jiao et al., 2017). Researches also elucidated
that PARP inhibitor olaparib enhanced CD8+ T-cell
recruitment and activation by activating the cGAS/STING
pathway in BRCA1-deﬁcient triple-negative breast cancer
(Pantelidou et al., 2019). Therefore, multiple combination
studies involving immune checkpoint inhibitors with DDR
inhibitors are undergoing clinical trials, such as combination
PARP inhibitor Niraparib and anti-PD-1 antibody
pembrolizumab in patients with triple-negative breast
cancer or ovarian cancer (NCT02657889). In the phase I,
multi-center, dose-escalation study, patients with advanced
solid tumors will receive WEE1 inhibitor AZD1775
(Adavosertib)
in
combination
with
MEDI4736
(durvalumab) (NCT02546661). These studies suggest that
DRC plays a key role in cancer therapy resistance,
therefore, evaluation of DNA repair phenotype before
treatment could be of great value in clinical management of
clinical therapeutic drugs or modalities.
A number of DDR inhibitors have currently come to market
or under clinical development. PARP inhibitors are the ﬁrst
clinically approved DDR drugs based on the concept of
“synthetic lethal” (Lord and Ashworth, 2017). PARP
inhibitors have been widely used for cancer patients with
BRCA1/2 mutation or HRR deﬁciency and showed promising
clinical activity. However, resistance inevitably developed in the
majority of patients and led to treatment failure. The
mechanism of resistance to PARP inhibitors can be innate or
acquired though clinical and preclinical studies. Preclinical
studies demonstrated that overexpression of P-glycoprotein
drug efﬂux transporter implicated in intrinsic resistance to
Olaparib (Henneman et al., 2015). Resumption of
PARformation due to poly (ADP-ribose) glycohydrolase
(PARG) depletion conferred acquired resistance to PARP
inhibition in BRCA2-deﬁcient tumor cells (Gogola et al.,
2018). PARP1 p. T910A mutation could override PARP1
inhibition promoted the secondary failure of Olaparib
treatment (Gröschel et al., 2019). Another mechanism
leading to resistance may restoration of HRR function or reconstruction of replication fork stability by increasing RAD51
expression or re-expressing BRCA1/2 (Ter Brugge et al., 2016;
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Quigley et al., 2017; Clements et al., 2018; Lim et al., 2018;
Marzio et al., 2019). Upregulation of certain oncogenic
pathways such as Wnt/β-catenin signaling pathway or DDR
related protein may also confer cancer cells insensitive to PARP
inhibitors and providing some rationale for combination
strategies with PARP inhibitors (Fukumoto et al., 2019;
Watson et al., 2019; Liu et al., 2020).

CONCLUSION AND PERSPECTIVES
Based on the relationship between DNA repair pathways and
cancer development and progression, a new therapeutic
strategy has emerged to increase the efﬁcacy of DNA
damaging agents through combination with inhibitors of
DNA repair pathways. The inhibitors of several DNA repair
pathways have been developed, and some of them are currently
undergoing clinical trials. The therapeutic beneﬁts of these
agents should be further evaluated in cancer treatment, and the
more speciﬁc inhibitors should be developed to reduce the
adverse effect on normal tissues and cells. Many studies have
demonstrated that the inhibition of DNA repair pathways may
be an important way in anticancer therapies. However, we
should realize that use of certain inhibitors of DNA repair
pathways may have potential drawbacks. The combination of
IR or chemotherapeutic agents with inhibitors of DNA repair
pathway may increase the mutagenic lesions in surviving cells
and lead to the development of secondary tumors. More
attentions have been paid to the relationship between
defective nuclear DNA repair pathway and therapeutic
resistance but less about the association between the
mitochondrial repair pathway and cancer cells. Due to the
difference in mtDNA between cancer cells and normal cells,
the development of mtDNA repair pathway inhibitors that can
reduce the adverse effects to normal cells may be a more
effective strategy to enhance the anticancer therapy than
targeting nDNA. A better understanding on the
mechanisms of mtDNA repair pathways shall facilitate the
development of new effective chemo- and radiosensitizers by
targeting mtDNA repair pathway in cancer therapy.
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